Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial-stage biotechnology company, announced that members of its management team will participate in one-on-one meetings at BTIG’s Infectious Disease Day 2026, which will be held virtually on June 16, 2026. Seth Lederman, M.D., president and chief executive officer of Tonix Pharmaceuticals, will represent the company during the event. The announcement highlights Tonix’s expanding focus on infectious disease and immunology, areas of high unmet medical need.
Tonix Pharmaceuticals is best known for its recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8 mg), the first new treatment for fibromyalgia in more than 15 years. However, the company’s pipeline extends well beyond central nervous system (CNS) disorders. According to the press release, Tonix is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The participation in BTIG Infectious Disease Day signals the company’s commitment to these infectious disease and immunology assets.
The BTIG Infectious Disease Day is a focused event bringing together industry leaders, investors, and researchers to discuss the latest developments in infectious disease. For Tonix, this is an opportunity to present its immunology pipeline to a targeted audience. The company’s Lyme disease prophylaxis candidate, TNX-4800, is particularly noteworthy given the rising incidence of Lyme disease in the United States and the lack of preventive treatments. Similarly, TNX-1500 addresses the need for improved immunosuppressive therapies in transplantation.
Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, the CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease.
Investors interested in the latest news and updates relating to TNXP can visit the company’s newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/38XUG.
Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. The participation in BTIG Infectious Disease Day 2026 underscores Tonix’s strategic shift toward broadening its portfolio beyond CNS to include infectious disease and immunology, potentially addressing significant unmet medical needs.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Tonix Pharmaceuticals to Present at BTIG Infectious Disease Day 2026.